Evidence map›Paper›PMID 40586933›Full record

ArticleCellular and molecular life sciences : CMLS2025

PAK1 regulates oligodendroglial proliferation and repopulation in homeostatic and demyelinating brain.

Yan Wang, Bokyung Kim, Xiangyi Shi, Huimin Chen, Joohyun Park, Meina Zhu, Evelyn M Wong, Audrey Y Park, Jonathan Chernoff, Fuzheng Guo

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan WangDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Bokyung KimDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Xiangyi ShiDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Huimin ChenDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Joohyun ParkDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Meina ZhuDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Evelyn M WongDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Audrey Y ParkDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA.
Jonathan ChernoffCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Fuzheng GuoDepartment of Neurology, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children, 2425 Stockton Blvd., Sacramento, CA, 95817, USA. fzguo@ucdavis.edu.ORCID http://orcid.org/0000-0003-3410-8389

Funding

The curious case of PARP1 in CNS myelin formation and repairR01NS123165 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Fuzheng Guo · 2022 to 2026
$2.5M
Glial HIFa: mechanisms and implications in hypoxia/ischemia-induced oligodendroglial pathologyR01NS123080 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GUO, FUZHENG · 2021 to 2025
$2.3M
SOX2-regulated astrocyte homeostasis and pathophysiologyR01NS134887 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Fuzheng Guo · 2024 to 2026
$1.8M
Using genetic approaches to explore the role of group I PAKs in developmental myelination of the mammalian CNSR21NS125464 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GUO, FUZHENG · 2022 to 2022
$439k
NINDS NIH HHS R01 NS123080NINDS NIH HHS R01NS123080NINDS NIH HHS R01 NS123165NINDS NIH HHS R01NS123165NINDS NIH HHS R01 NS134887NINDS NIH HHS R01NS134887NINDS NIH HHS R21 NS125464NINDS NIH HHS R21NS125464Shriners Hospitals for Children 85101-NCA-22Shriners Hospitals for Children 85113-NCA-23Shriners Hospitals for Children 85410-NCA-24
6 · The paper itself

Abstract

Activating mutations in p21-activated kinase 1 (PAK1) cause intellectual disability, neurodevelopmental abnormality, macrocephaly, and white matter anomaly in children. Oligodendroglial lineage cells undergo extensive proliferation and population expansion in human and rodent brain during early postnatal development. It remains unclear if and how PAK1 regulates oligodendroglial development. Here, using a series of genetic mouse models, we show that PAK1 controls oligodendroglial progenitor cell (OPC) proliferation and regeneration during normal brain development and in brain white matter injury. Unlike differentiating oligodendrocytes, OPCs display high levels of PAK1 kinase activity which maintains them in a proliferative progenitor state through modulating PDGFRa-mediated mitogenic signaling and acts as a molecular brake limiting OPC differentiation. PAK1-deficient or kinase-inhibited OPCs reduce their proliferation capacity and population expansion in a cell-autonomous manner. Transgenic mice carrying OPC-specific PAK1 deletion or kinase inhibition are populated with fewer OPCs in the homeostatic brain. Furthermore, OPC proliferation and intra-lesional repopulation are significantly impaired in mice of OPC-specific PAK1 deletion or kinase inhibition after white matter injury. Together, our findings suggest that kinase-activating PAK1 mutations stall OPCs in a proliferative progenitor state, impacting timely oligodendroglial differentiation in the CNS of affected children and that PAK1 is a potential molecular target for replenishing OPCs in demyelinating lesions.

Indexed as

BrainDemyelinating DiseasesOligodendrogliap21-Activated KinasesAnimalsCell DifferentiationCell ProliferationHomeostasisHumansMiceMice, TransgenicReceptor, Platelet-Derived Growth Factor alphaSignal TransductionWhite Matterp21-Activated KinasesPak1 protein, mouseReceptor, Platelet-Derived Growth Factor alphaDemyelinating brainHomeostatic brainOligodendrocyteOPC proliferationp21-activated kinase 1PAK1

Identifiers

PMID40586933
PMCPMC12209112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.